drugset / Trial / NCT03443570
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
Phase 3
Unknown
200 enrolled
Shandong University
The Affiliated Hospital of Qingdao University · collabYantai Yuhuangding Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The project was undertaking by Qilu Hospital of Shandong University and other 2 well-known hospitals in China. In order to report the efficacy and safety of rituximab combining with bortezomib for the treatment of adults with immune thrombocytopenia (ITP), compared to rituximab alone .
Timeline
- Start
- 2018-03-01
- Primary completion
- 2020-03-01
- Completion
- 2021-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 2 mg | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 500 mg | Intravenous |